Display options
Cite
Zhang H, Orme JJ, Abraha F, et al. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in . Clin Cancer Res. 2021;27(23):6376-6383doi: 10.1158/1078-0432.CCR-21-2510.
Zhang, H., Orme, J. J., Abraha, F., Stish, B. J., Lowe, V. J., Lucien, F., Tryggestad, E. J., Bold, M. S., Pagliaro, L. C., Choo, C. R., Brinkmann, D. H., Iott, M. J., Davis, B. J., Quevedo, J. F., Harmsen, W. S., Costello, B. A., Johnson, G. B., Nathan, M. A., Olivier, K. R., Pisansky, T. M., Kwon, E. D., Dong, H., & Park, S. S. (2021). Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(23), 6376-6383. https://doi.org/10.1158/1078-0432.CCR-21-2510
Zhang, Henan, et al. "Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,23 (2021): 6376-6383. doi: https://doi.org/10.1158/1078-0432.CCR-21-2510
Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in . Clin Cancer Res. 2021 Dec 01;27(23):6376-6383. doi: 10.1158/1078-0432.CCR-21-2510. Epub 2021 Sep 30. PMID: 34593526; PMCID: PMC8639778.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2021 Dec 01;27(23):6376-6383. doi: 10.1158/1078-0432.CCR-21-2510. Epub 2021 Sep 30.

Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in .

Clinical cancer research : an official journal of the American Association for Cancer Research

Henan Zhang, Jacob J Orme, Feven Abraha, B J Stish, Val J Lowe, Fabrice Lucien, Erik J Tryggestad, Michael S Bold, Lance C Pagliaro, C Richard Choo, Debra H Brinkmann, Matthew J Iott, Brian J Davis, J Fernando Quevedo, William S Harmsen, Brian A Costello, Geoffrey B Johnson, Mark A Nathan, Kenneth R Olivier, Thomas M Pisansky, Eugene D Kwon, Haidong Dong, Sean S Park

Affiliations

  1. Departments of Urology and Immunology, Mayo Clinic, Rochester, Minnesota.
  2. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  3. Department of Biostatistics and Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  4. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
  5. Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota.
  6. Departments of Urology and Immunology, Mayo Clinic, Rochester, Minnesota. [email protected] [email protected].
  7. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. [email protected] [email protected].

PMID: 34593526 PMCID: PMC8639778 DOI: 10.1158/1078-0432.CCR-21-2510

Abstract

PURPOSE: Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers are lacking.

PATIENTS AND METHODS: Eighty-nine patients with oligometastatic CRPC were identified by

RESULTS: 128 lesions in 89 patients were included in this analysis. Median OS was 29.3 months, and 1- and 2-year OS were 96% and 80%, respectively. PSA PFS was 40% at 1 year and 21% at 2 years. Local PFS was 84.4% and 75.3% at 1 and 2 years, respectively, and no grade ≥3 AEs were observed. Baseline high levels of tumor-reactive T cells (T

CONCLUSIONS: This is the first comprehensive effector T-cell immunophenotype analysis in a phase II trial before and after SABR in CRPC. Results are favorable and support the incorporation of immune-based markers in the design of future randomized trials in patients with oligometastatic CRPC treated with SABR.

©2021 American Association for Cancer Research.

References

  1. Cell Rep. 2021 Feb 16;34(7):108744 - PubMed
  2. Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39 - PubMed
  3. JCI Insight. 2016 May 5;1(6): - PubMed
  4. J Clin Oncol. 2016 Apr 20;34(12):1402-18 - PubMed
  5. Adv Radiat Oncol. 2019 Feb 19;4(2):314-322 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):160-4 - PubMed
  7. Front Oncol. 2013 Jan 22;2:215 - PubMed
  8. J Clin Oncol. 2009 May 20;27(15):2450-6 - PubMed
  9. JAMA Oncol. 2021 Jun 1;7(6):845-852 - PubMed
  10. JCI Insight. 2018 Apr 19;3(8): - PubMed
  11. Oncoimmunology. 2013 Jun 1;2(6):e23972 - PubMed
  12. Med Phys. 2010 Aug;37(8):4078-101 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):229-240 - PubMed
  14. J Clin Oncol. 2020 Sep 1;38(25):2830-2838 - PubMed
  15. J Cancer Res Ther. 2021 Apr-Jun;17(2):358-365 - PubMed
  16. J Clin Oncol. 2018 Feb 10;36(5):446-453 - PubMed
  17. J Nucl Med. 2003 Mar;44(3):331-5 - PubMed
  18. Ann Oncol. 2018 Aug 1;29(8):1807-1813 - PubMed
  19. World J Urol. 2019 Dec;37(12):2631-2637 - PubMed
  20. World J Urol. 2019 Dec;37(12):2545-2547 - PubMed
  21. JAMA Oncol. 2020 May 1;6(5):650-659 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702 - PubMed
  23. Clin Cancer Res. 2005 May 1;11(9):3353-62 - PubMed
  24. Prostate. 2019 Feb;79(3):244-258 - PubMed
  25. J Urol. 2013 Apr;189(4):1308-13 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 - PubMed
  27. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  28. Lancet Oncol. 2016 Dec;17(12):1672-1682 - PubMed
  29. JAMA Oncol. 2020 Feb 1;6(2):185-186 - PubMed
  30. Pract Radiat Oncol. 2014 Mar-Apr;4(2):76-81 - PubMed
  31. Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):253-63 - PubMed
  32. J Immunol. 2005 Jun 15;174(12):7516-23 - PubMed
  33. Cancer Immunol Res. 2015 Jun;3(6):610-9 - PubMed

Publication Types

Grant support